CU24608B1 - Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos - Google Patents

Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos

Info

Publication number
CU24608B1
CU24608B1 CU2020000008A CU20200008A CU24608B1 CU 24608 B1 CU24608 B1 CU 24608B1 CU 2020000008 A CU2020000008 A CU 2020000008A CU 20200008 A CU20200008 A CU 20200008A CU 24608 B1 CU24608 B1 CU 24608B1
Authority
CU
Cuba
Prior art keywords
compounds
useful
treatment
dihydrooxadiazinones
substituted
Prior art date
Application number
CU2020000008A
Other languages
English (en)
Other versions
CU20200008A7 (es
Inventor
Alex Burgin
Dr Manuel Ellermann
Dr Stefan Nikolaus Gradl
Heidi Greulich
Prof Dr Christa Hegele-Hartung
Dr Charlotte Kopitz
Dr Martin Lange
Timothy Lewis
Dr Philip Lienau
Prof Matthew Meyerson
Dr Detlev Sülzle
Dr Adrian Tersteegen
Xiaoyun Wu
Original Assignee
Bayer Ag
Bayer Pharma AG
Dana Farber Cancer Inst Inc
Broad Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG, Dana Farber Cancer Inst Inc, Broad Inst Inc filed Critical Bayer Ag
Publication of CU20200008A7 publication Critical patent/CU20200008A7/es
Publication of CU24608B1 publication Critical patent/CU24608B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/04—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>La invención proporciona compuestos de dihidrooxidiazinona de Ia fórmula general (I):</p> <p>ESPACIO PARA FÓRMULA</p> <p>en donde R1, R2, R3, y R4 son como se definen en el presente, procedimientos para Ia<br /> preparación de dichos compuestos, compuestos intermedios útiles para Ia preparación de dichos compuestos, los cuales son útiles para el tratamiento o Ia profilaxis de enfermedades, en especial de enfermedades hiperproliferativas.</p>
CU2020000008A 2017-08-04 2018-08-02 Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos CU24608B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541627P 2017-08-04 2017-08-04
PCT/EP2018/071039 WO2019025562A1 (en) 2017-08-04 2018-08-02 DIHYDROOXADIAZINONES

Publications (2)

Publication Number Publication Date
CU20200008A7 CU20200008A7 (es) 2020-11-30
CU24608B1 true CU24608B1 (es) 2022-06-06

Family

ID=63207725

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000008A CU24608B1 (es) 2017-08-04 2018-08-02 Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos

Country Status (25)

Country Link
US (3) US11427553B2 (es)
EP (1) EP3661517B1 (es)
JP (2) JP2020529439A (es)
KR (1) KR20200036914A (es)
CN (1) CN111212647B (es)
AR (1) AR112402A1 (es)
AU (1) AU2018309356B2 (es)
BR (1) BR112020002351A2 (es)
CA (1) CA3071800A1 (es)
CL (1) CL2020000303A1 (es)
CO (1) CO2020001242A2 (es)
CR (1) CR20200057A (es)
CU (1) CU24608B1 (es)
EA (1) EA202090448A1 (es)
EC (1) ECSP20008441A (es)
IL (1) IL272098B2 (es)
JO (1) JOP20200024A1 (es)
MA (1) MA49750A (es)
MX (1) MX2020001404A (es)
PH (1) PH12020500134A1 (es)
SG (1) SG11201913775UA (es)
TW (1) TWI791581B (es)
UA (1) UA125731C2 (es)
UY (1) UY37832A (es)
WO (1) WO2019025562A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
WO2020157188A1 (en) * 2019-02-01 2020-08-06 Bayer Aktiengesellschaft Dihydrooxadiazinones for the treatment of hyperproliferative diseases
EP4301371A1 (en) 2021-03-03 2024-01-10 Bayer Aktiengesellschaft Substituted 3,6-dihydro-2h-1,3,4-oxadiazin-2-ones for the treatment of sarcoma
EP4289828A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Method for the preparation of a 3,6-dihydro-2h-1,3,4-oxadiazin-2-one
EP4289829A1 (en) 2022-06-10 2023-12-13 Bayer Aktiengesellschaft Crystalline forms of (6s)-5-[4'-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro- 2h-1,3,4-oxadiazin-2-one
WO2024109919A1 (zh) * 2022-11-24 2024-05-30 盛睿泽华医药科技（苏州）有限公司 吡啶酮化合物及其制备方法和用途
CN117903077B (zh) * 2023-01-13 2024-09-03 上海超阳药业有限公司 二氢噁二嗪酮化合物及其应用
CN118420559A (zh) * 2023-04-27 2024-08-02 上海超阳药业有限公司 氘代噁二嗪酮化合物及其用途
CN118047833A (zh) * 2024-01-31 2024-05-17 海南大学 含二茂铁的取代氨基乙酰胺类化合物及其制备方法和应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4097671A (en) * 1975-08-28 1978-06-27 General Electric Company Dihydrooxadiazinones and method for making
US4052395A (en) 1975-09-11 1977-10-04 Sankyo Company Limited Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones
US4258094A (en) * 1979-04-26 1981-03-24 Brunswick Corporation Melt bonded fabrics and a method for their production
US4334030A (en) 1979-11-23 1982-06-08 General Electric Company Thermoplastic foamable blends
DE3172252D1 (en) 1980-11-14 1985-10-17 Ici Plc Heterocyclic compounds
ATE13294T1 (de) 1981-03-04 1985-06-15 Ciba Geigy Ag Pyridazinone, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und deren verwendung.
US4495185A (en) 1981-11-12 1985-01-22 Imperial Chemical Industries, Plc 1,2,4-Triazin-3(2H) ones
ZA827641B (en) 1981-11-12 1983-09-28 Ici Plc Thiadiazine, oxadiazine and triazine derivatives which possess cardiotonic and/or antihypertensive activity
US4581356A (en) 1983-03-22 1986-04-08 Fujisawa Pharmaceutical Co., Ltd. Triazine derivatives, and pharmaceutical compositions comprising the same
GB8310435D0 (en) 1983-04-18 1983-05-25 Fujisawa Pharmaceutical Co Triazine derivatives
JPS59196874A (ja) 1983-04-22 1984-11-08 Fujisawa Pharmaceut Co Ltd トリアジン誘導体
JPS6153270A (ja) 1984-08-17 1986-03-17 チバ・ガイギー・アクチエンゲゼルシヤフト 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
GB8426804D0 (en) 1984-10-23 1984-11-28 Ciba Geigy Ag Pyridazinones preparations
ZW20586A1 (en) 1985-10-17 1988-05-25 Smith Kline French Lab Chemical compounds
EP0303418A3 (en) 1987-08-11 1990-11-07 Smithkline Beecham Laboratoires Pharmaceutiques Substituted indolones, useful in the treatment of heart or asthmatic diseases
EP0478195B1 (en) 1990-09-21 1999-05-26 Rohm And Haas Company Dihydropyridazinones and pyridazinones as fungicides
JPH0676325B2 (ja) * 1992-05-08 1994-09-28 三井東圧化学株式会社 オキサジアジン誘導体を有効成分として含有する抗血栓剤
DK0650480T3 (da) 1992-07-01 2002-05-13 Ortho Pharma Corp 1-Arylsulfonyl-3-phenyl-1,4,5,6-tetrahydropyridaziner
JPH07291968A (ja) 1994-04-26 1995-11-07 Mitsubishi Chem Corp トリアジノン誘導体またはその塩類
DE19929787A1 (de) 1999-06-29 2001-01-04 Bayer Ag Neue 4-(2-Oxodihydrooxadiazinylphenyl)amide und ihre Verwendung
EP1368035A1 (en) 2001-02-12 2003-12-10 MERCK PATENT GmbH Use of type 4 phosphodiesterase inhibitors in myocardial diseases
WO2008108602A1 (en) 2007-03-07 2008-09-12 Dong-A Pharm. Co., Ltd. Novel phenylpropionic acid derivatives as peroxisome proliferator-activated gamma receptor modulators, method of the same, and pharmaceutical composition comprising the same
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
FR2948940B1 (fr) 2009-08-04 2011-07-22 Servier Lab Nouveaux derives dihydroindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US8772323B2 (en) 2010-05-07 2014-07-08 Boehringer Ingelheim International Gmbh Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
TWI532742B (zh) 2011-02-28 2016-05-11 艾伯維有限公司 激酶之三環抑制劑
EP2970145B1 (en) * 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
CN114699528A (zh) 2015-08-13 2022-07-05 布罗德研究所股份有限公司 用于表达pde3a或slfn12的癌症的组合物和方法
WO2017121684A1 (en) 2016-01-14 2017-07-20 Bayer Pharma Aktiengesellschaft 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
CN114601837A (zh) 2016-02-05 2022-06-10 拜耳医药股份公司 用于癌症患者分级和癌症治疗的化合物、组合物和方法
KR101831772B1 (ko) * 2016-03-24 2018-03-06 아이디에스(주) 복합 광원 모듈을 가지는 카메라 접사용 기구 및 이를 이용한 지문 시편 촬영 방법
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
EP3661917B1 (en) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3873922A4 (en) 2018-11-01 2022-08-03 The Broad Institute, Inc. IDENTIFICATION OF TUMORS RESPONSIVE TO PDE3 MODULATORS
WO2020157194A1 (en) 2019-02-01 2020-08-06 Bayer Aktiengesellschaft 1,2,4-triazin-3(2h)-one compounds for the treatment of hyperproliferative diseases

Also Published As

Publication number Publication date
US11773070B2 (en) 2023-10-03
JP2023115065A (ja) 2023-08-18
WO2019025562A1 (en) 2019-02-07
CL2020000303A1 (es) 2020-11-13
IL272098B2 (en) 2023-07-01
UY37832A (es) 2019-02-28
IL272098B1 (en) 2023-03-01
PH12020500134A1 (en) 2021-01-25
CU20200008A7 (es) 2020-11-30
EP3661517A1 (en) 2020-06-10
SG11201913775UA (en) 2020-01-30
BR112020002351A2 (pt) 2020-09-08
AU2018309356A1 (en) 2020-01-30
JP2020529439A (ja) 2020-10-08
TWI791581B (zh) 2023-02-11
AR112402A1 (es) 2019-10-23
CO2020001242A2 (es) 2020-02-18
US20200369633A1 (en) 2020-11-26
ECSP20008441A (es) 2020-05-29
CR20200057A (es) 2020-06-16
CN111212647B (zh) 2024-05-14
KR20200036914A (ko) 2020-04-07
CA3071800A1 (en) 2019-02-07
EP3661517B1 (en) 2023-09-13
US20230017200A1 (en) 2023-01-19
MA49750A (fr) 2020-06-10
UA125731C2 (uk) 2022-05-25
EA202090448A1 (ru) 2020-05-21
TW201917126A (zh) 2019-05-01
JOP20200024A1 (ar) 2020-02-02
US20220396554A1 (en) 2022-12-15
CN111212647A (zh) 2020-05-29
IL272098A (en) 2020-03-31
MX2020001404A (es) 2020-03-12
US11427553B2 (en) 2022-08-30
AU2018309356B2 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2017001426A1 (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CR20160241A (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b
NI201800128A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CR20160337A (es) Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
DOP2015000157A (es) Lactamas fusionadas de arilo y heteroarilo
CU24408B1 (es) Compuestos de dihidroisoquinolinona sustituida
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
CO2020002961A2 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c&#39;] dipyrrol-2-yl
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
CL2020001107A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
CY1121709T1 (el) Παραγωγο τετραϋδροπυρρολο[3,4-d][1,3]θειαζινης ως αναστολεας της bace
DOP2017000196A (es) Derivados de tetrahidropiranil benzamida
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina
CO2021002415A2 (es) Derivados de heteroarilo bicíclicos